Gilead, AstraZeneca/Daiichi Sankyo offer first look at TROP2 ADCs in first-line lung cancer as rivalry heats up 

11 Sep 2023
ADCPhase 3Drug ApprovalAccelerated Approval
Preliminary mid-stage data from two rival TROP2-targeting ADCs advanced by AstraZeneca/Daiichi Sankyo and Gilead, combined with immune checkpoint inhibitors, have provided a first glance at the risk-benefit balance of this approach in non-small cell lung cancer. And although Gilead noticed a slightly higher response rate, analysts called the results “broadly similar.” Both AstraZeneca’s Dato-DXd and Gilead’s Trodelvy comprise an antibody that targets the TROP2 receptor linked with a DNA topoisomerase 1 inhibitorDNA topoisomerase 1 inhibitor. Dato-DXd is an investigational program in Phase III for breast cancer and NSCLC, while Trodelvy is approved as a single agent for certain forms of breast cancer and has won accelerated approval for bladder cancer.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.